We can’t show the full text here under this license. Use the link below to read it at the source.
Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
Switching between two types of immune checkpoint blockers for repeated treatment in advanced lung cancer: Case reports and review
AI simplified
Abstract
Among 17 patients with advanced or recurrent non-small cell lung cancer, one (5.9%) achieved partial response after immune checkpoint inhibitor rechallenge.
- Nine patients (52.9%) had stable disease following the rechallenge with .
- The median after rechallenge was 4.0 months (range: 0.4-8.0 months).
- The median from the initial immune checkpoint inhibitor treatment was 31.0 months (range: 7.6-46.8 months).
- Of 10 patients with immune-related adverse events during the first treatment, five experienced these events again after rechallenge.
- Four patients had relapsed immune-related adverse events, with two experiencing grade 3 or higher pneumonitis.
- Almost all immune-related adverse events during rechallenge were manageable.
AI simplified
Key numbers
1 of 17
Partial Response Rate
One patient achieved partial response after rechallenge.
9 of 17
Stable Disease Rate
Nine patients achieved stable disease after ICI rechallenge.
4.0 months
Median
Median after switching was 4.0 months.